Overview
Welcome to Dwaey, specifically on RANEXA 500 Tablets/Prolonged Release page.
This medicine contains an important and useful components, as it consists of Ranolazine.
RANEXA 500 is available in the market in concentration 500mg/Tablet and in the form of Tablets/Prolonged Release.
MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG SA is the producer of RANEXA 500 and it is imported from LUXEMBOURG, The most popular alternatives of RANEXA 500 are listed downward .
Ranolazine exert its antianginal and anti-ischaemic effects through concentration-, voltage-, and frequency-dependent inhibition of the late Na current and other cardiac ion channels and transporters. It may decrease the magnitude of the late Na current resulting in a net reduction in intracellular Na concentrations, reversal of Ca overload, restoration of ventricular pump function, and prevention of ischaemia-induced arrhythmias. Its antianginal effects are not dependent upon reductions in heart rate or BP and QT interval prolongation effect is caused by inhibition of rapid delayed rectifier K current (IKr), which prolongs the ventricular action potential.
Heart rhythm problems (e.g., bradycardia, QT prolongation, ventricular tachycardia), liver problems, certain uncorrected mineral imbalances (low potassium/magnesium levels), severe kidney problems. Lactation: Unknown if excreted in breast milk; discontinue or do not nurse
Taking strong inhibitors of CYP3A (e.g., ketoconazole, clarithromycin, nelfinavir) Taking inducers of CYP3A (e.g., phenobarbital, rifampicin)Significant hepatic impairment
Pregnancy category: C
Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks